(Q40406133)

20 September 2017

title

BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis B virus infection (2005). (English)

1 reference

20 September 2017

1 reference

M G Brook

1

1 reference

20 September 2017

R Gilson

2

1 reference

20 September 2017

E Wilkins

3

1 reference

20 September 2017

BHIVA Hepatitis Coinfection Guideline Committee

4

1 reference

20 September 2017

British HIV Association

5

1 reference

20 September 2017

publication date

1 July 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

6 Suppl 2

1 reference

20 September 2017

page(s)

84-95

1 reference

Case-control study of sexually transmitted diseases as cofactors for HIV-1 transmission.

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Seroprevalence of hepatitis B and C and HIV in Malawian pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Hepatitis B and C infections, human immunodeficiency virus and other sexually transmitted infections among women of childbearing age in Côte d'Ivoire, West Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

The interaction of human immunodeficiency virus infection and hepatitis B virus infection in infected homosexual men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Are booster immunisations needed for lifelong hepatitis B immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Fatal liver failure in haemophiliacs with HIV-induced immunodeficiency: observation of six patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Global control of hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Treatment of chronic hepatitis B: case selection and duration of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

Failure of combination therapy with lamivudine and famciclovir following lamivudine monotherapy for hepatitis B virus infection in patients coinfected with human immunodeficiency virus-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00301.X

10.1111/J.1468-1293.2005.00301.X

21 January 2018

Identifiers

DOI

1 reference

20 September 2017

1 reference